Erman Akkus: KEYNOTE-585 – although pathological complete response improved, no survival advantage

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:

“KEYNOTE-585: Neoadjuvant and adjuvant pembro+chemo in locally advanced gastric/GE cancer in The Lancet Oncology.

• 804 patients
• 3xPembro/placebo+chemo >surgery > 3xPembro/placebo+chemo > 11pembro/placebo
• pCR: 12.9% vs 2%, p<0.00001
• Median event free survival: 44.4 mo vs 25.3 mo (HR: 0.81, p=0.01)
• Median OS: 60.7 mo vs 58 mo, p=0.17

Although pathological complete response improved, no survival advantage.” 

Source: Erman Akkus/X